FEATURED COMPANIES
- ANIKA THERAPEUTICS, INC.
- F.HOFFMANN-LA ROCHE LTD.
- FERRING B.V.
- FIDIA FARMACEUTIC S.P.A
- SALIX PHARMACEUTICALS
- SANOFI
The global viscosupplementation market size is expected to reach USD 7.8 billion by 2027. It is anticipated to exhibit a CAGR of 9.2% during the forecast period. Improving regulatory and reimbursement scenarios regarding the use of viscosupplements for the treatment of Osteoarthritis (OA) is expected to aid the growth. For instance, in the U.S., unique reimbursement codes are allocated for different products available in the country.
Viscosupplementation procedure is an effective alternative for patients nonresponsive to other treatment options for osteoarthritis. These products have been clinically proven to be effective in providing long-term relief to OA patients with very few side-effects. Factors, such as the growing awareness regarding effective non-surgical procedures for the management of OA and global increase in the target population due to the increasing prevalence of obesity and other lifestyle-induced disorders, are expected to propel the market growth during the forecast period.
Further key findings from the study suggest:
Viscosupplementation procedure is an effective alternative for patients nonresponsive to other treatment options for osteoarthritis. These products have been clinically proven to be effective in providing long-term relief to OA patients with very few side-effects. Factors, such as the growing awareness regarding effective non-surgical procedures for the management of OA and global increase in the target population due to the increasing prevalence of obesity and other lifestyle-induced disorders, are expected to propel the market growth during the forecast period.
Further key findings from the study suggest:
- Three injections segment dominated the market in 2019 owing to the availability of multiple products and significant market presence
- Single injection segment is anticipated to witness the fastest growth during the forecast period owing to the increase in demand for a shorter regimen of procedures and faster recovery time
- The utilization of viscosupplementation is maximum in Ambulatory Surgical Centers (ASCs), and orthopedic clinics. The higher usage of the viscosupplements is observed to be in outpatient settings owing to better reimbursement options
- General physicians, rheumatologists, and orthopedists are the main influencer in the viscosupplementation market. The role of an influencer in the procurement of the product in the hospitals and clinics varies from region to region
- Asia Pacific held the largest market share in 2019 and is expected to maintain its position during the forecast period due to the presence of key players and high incidence of osteoarthritis in the countries such as Japan and China.
- Europe is expected to witness a lucrative CAGR in the forthcoming years, due to growing awareness about applications of non-surgical techniques and increasing disposable income
- Key players are investing in improving their product portfolio to develop advanced products to maintain their market position. For instance, in March 2019, Seikagaku Corporation introduced a new intra-articular viscosupplement named HyLink (single injection) in Italy for the treatment of knee OA
- Companies are also undertaking strategic initiatives, such as marketing licensing and distribution partnerships to increase geographic presence
- Some key industry contributors are Anika Therapeutics, Inc., Sanofi, Ferring B.V., Seikagaku Corporation, Bioventus, Zimmer Holdings Inc, LG Life Sciences Ltd, and Lifecore Biomedical, LLC
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- ANIKA THERAPEUTICS, INC.
- F.HOFFMANN-LA ROCHE LTD.
- FERRING B.V.
- FIDIA FARMACEUTIC S.P.A
- SALIX PHARMACEUTICALS
- SANOFI
Chapter 1 Research Objective
1.1 Objectives
1.1.1 Objective 1
1.1.2 Objective 2
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.2.1 Product
2.2.2 End-Use
2.2.3 Region
2.3 Competitive Insights
Chapter 3 Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Market Segmentation
3.3 User Perspective Analysis
3.3.1 Consumer Behavior Analysis
3.3.2 Market Influencer Analysis
3.4 Penetration & Growth Prospect Mapping
3.4.1 Analysis
3.5 Market Dynamics
3.5.1 Market Driver Analysis
3.5.1.1 Increasing prevalence of osteoarthritis among geriatric population
3.5.1.2 New product launch
3.5.2 Market Restraint Analysis
3.5.2.1 High cost and side effects associated with hyaluronic acid cycles
3.6 Business Environment Analysis Tools
3.6.1 Porter’s Five Forces Analysis
3.6.2 Viscosupplementation Market - Pestle Analysis
3.7 Clinical Trials
3.8 Major Deals & Strategic Alliances Analysis
3.8.1 Licensing & Partnerships, Technology Collaborations
3.8.2 Mergers & Acquisitions
Chapter 4 Viscosupplementation Market: Product Analysis
4.1 Viscosupplementation Product Market Share analysis, 2019 & 2027
4.2 Segment Dashboard
4.3 Market Size & Forecasts and Trend Analysis, 2016 to 2027 for the Product
4.3.1 Single Injection
4.3.1.1 Single injection market, 2016 - 2027 (USD Million)
4.3.2 Three Injection
4.3.2.1 Three injection market, 2016 - 2027 (USD Million)
4.3.3 Five Injection
4.3.3.1 Five injection market, 2016 - 2027 (USD Million)
4.3.4 Product Information
4.3.4.1 Durolane
4.3.4.2 GelSyn-3
4.3.4.3 GenVisc 850
4.3.4.4 Hymovis
4.3.4.5 Supartz FX
4.3.4.6 TriVisc
4.3.4.7 Visco-3
4.3.4.8 Ostenil
4.3.4.9 Adant
Chapter 5 Viscosupplementation Market: End-Use Analysis
5.1 Viscosupplementation End-Use Market Share analysis, 2019 & 2027
5.2 Segment Dashboard
5.3 Market Size & Forecasts and Trend Analysis, 2016 to 2027 for the End-Use
5.3.1 Hospitals
5.3.1.1 Hospitals market, 2016 - 2027 (USD Million)
5.3.2 Orthopedic Clinics/Ambulatory Surgery Centers (Ascs)
5.3.2.1 Orthopedic clinic/ambulatory surgical centers market, 2016 - 2027 (USD Million)
Chapter 6 Regional Outlook
6.1 Regional Market Share Analysis, 2019 & 2027
6.2 Regional Market Snapshot (Countries)
6.3 SWOT Analysis, by Factor
6.3.1 North America
6.3.2 Europe
6.3.3 Asia Pacific
6.3.4 Latin America
6.3.5 Middle East & Africa
6.4 Market Size, & Forecasts and Trend Analysis, 2019 to 2027
6.4.1 North America
6.4.1.1 North America viscosupplementation market, 2016 - 2027 (USD Million)
6.4.1.2 U.S.
6.4.1.2.1 Regulatory and reimbursement scenario
6.4.1.2.2 U.S. viscosupplementation market, 2016 - 2027 (USD Million)
6.4.1.3 Canada
6.4.1.3.1 Regulatory and reimbursement scenario
6.4.1.3.2 Canada viscosupplementation market, 2016 - 2027 (USD Million)
6.4.2 Europe
6.4.2.1 Europe viscosupplementation market, 2016 - 2027 (USD Million)
6.4.2.2 U.K.
6.4.2.2.1 Regulatory and reimbursement scenario
6.4.2.2.2 U.K. viscosupplementation market, 2016 - 2027 (USD Million)
6.4.2.3 Germany
6.4.2.3.1 Regulatory and reimbursement scenario
6.4.2.3.2 Germany viscosupplementation market, 2016 - 2027 (USD Million)
6.4.2.4 France
6.4.2.4.1 Regulatory and reimbursement scenario
6.4.2.4.2 France viscosupplementation market, 2016 - 2027 (USD Million)
6.4.2.5 Italy
6.4.2.5.1 Regulatory and reimbursement scenario
6.4.2.5.2 Italy viscosupplementation market, 2016 - 2027 (USD Million)
6.4.2.6 Spain
6.4.2.6.1 Regulatory and reimbursement scenario
6.4.2.6.2 Spain viscosupplementation market, 2016 - 2027 (USD Million)
6.4.3 Asia Pacific
6.4.3.1 Asia Pacific viscosupplementation market, 2016 - 2027 (USD Million)
6.4.3.2 China
6.4.3.2.1 Regulatory and reimbursement scenario
6.4.3.2.1 China viscosupplementation market, 2016 - 2027 (USD Million)
6.4.3.3 Japan
6.4.3.3.1 Regulatory and reimbursement scenario
6.4.3.3.2 Japan viscosupplementation market, 2016 - 2027 (USD Million)
6.4.3.4 India
6.4.3.4.1 Regulatory and reimbursement scenario
6.4.3.4.2 India viscosupplementation market, 2016 - 2027 (USD Million)
6.4.3.5 South Korea
6.4.3.5.1 Regulatory and reimbursement scenario
6.4.3.5.2 South Korea viscosupplementation market, 2016 - 2027 (USD Million)
6.4.3.6 Australia
6.4.3.6.1 Regulatory and reimbursement scenario
6.4.3.6.2 Australia viscosupplementation market, 2016 - 2027 (USD Million)
6.4.4 Latin America
6.4.4.1 Latin America viscosupplementation market, 2016 - 2027 (USD Million)
6.4.4.2 Brazil
6.4.4.2.1 Regulatory and reimbursement scenario
6.4.4.2.2 Brazil viscosupplementation market, 2016 - 2027 (USD Million)
6.4.4.3 Mexico
6.4.4.3.1 Regulatory and reimbursement scenario
6.4.4.3.2 Mexico viscosupplementation market, 2016 - 2027 (USD Million)
6.4.4.4 Argentina
6.4.4.4.1 Regulatory and reimbursement scenario
6.4.4.4.2 Argentina viscosupplementation market, 2016 - 2027 (USD Million)
6.4.4.5 Columbia
6.4.4.5.1 Regulatory and reimbursement scenario
6.4.4.5.2 Columbia viscosupplementation market, 2016 - 2027 (USD Million)
6.4.5 Middle East & Africa
6.4.5.1 MEA viscosupplementation market, 2016 - 2027 (USD Million)
6.4.5.2 South Africa
6.4.5.2.1 Regulatory and reimbursement scenario
6.4.5.2.2 South africa viscosupplementation market, 2016 - 2027 (USD Million)
6.4.5.3 Saudi Arabia
6.4.5.3.1 Regulatory and reimbursement scenario
6.4.5.3.2 Saudi Arabia viscosupplementation market, 2016 - 2027 (USD Million)
6.4.5.4 UAE
6.4.5.4.1 Regulatory and reimbursement scenario
6.4.5.4.2 UAE viscosupplementation market, 2016 - 2027 (USD Million)
Chapter 7 Reimbursement Outlook
7.1 Direct Medical Costs of Treatment of Osteoarthritis (Percentage Distribution)
7.2 Cost of Products
7.3 Reimbursement by Product
7.3.1 Gel-One
7.3.2 Euflexxa
7.3.3 Synvisc-One
7.3.4 Supartz
7.3.5 Hyalgan
7.3.6 Monovisc
7.3.7 Orthovisc
Chapter 8 Competitive Analysis
8.1 Strategic Framework/ Competition Categorization (Key innovators, Market leaders, emerging players
8.2 Vendor Landscape
8.2.1 Company Market Position Analysis (Market Presence, Geographic Presence, Product Portfolio, Startegic Initiatves)
8.3 Company Profiles
8.3.1 SANOFI
8.3.1.1 Company overview
8.3.1.2 Financial performance
8.3.1.3 Product benchmarking
8.3.1.4 Strategic initiatives
8.3.1.5 SWOT analysis
8.3.2 ANIKA THERAPEUTICS, INC.
8.3.2.1 Company overview
8.3.2.2 Financial performance
8.3.2.3 Product benchmarking
8.3.2.4 Strategic initiatives
8.3.2.5 SWOT analysis
8.3.3 SEIKAGAKU CORPORATION
8.3.3.1 Company overview
8.3.3.2 Financial performance
8.3.3.3 Product benchmarking
8.3.3.4 Strategic initiatives
8.3.3.5 SWOT analysis
8.3.4 ZIMMER BIOMET
8.3.4.1 Company overview
8.3.4.2 Financial performance
8.3.4.3 Product benchmarking
8.3.4.4 Strategic initiatives
8.3.4.5 SWOT analysis
8.3.5 SMITH & NEPHEW PLC
8.3.5.1 Company overview
8.3.5.2 Financial performance
8.3.5.3 Product benchmarking
8.3.5.4 Strategic initiatives
8.3.5.5 SWOT analysis
8.3.6 FERRING B.V.
8.3.6.1 Company overview
8.3.6.2 Financial performance
8.3.6.3 Product benchmarking
8.3.6.4 Strategic initiative
8.3.7 LIFECORE BIOMEDICAL, LLC (LANDEC)
8.3.7.1 Company overview
8.3.7.2 Financial performance
8.3.7.3 Product benchmarking
8.3.7.4 Strategic initiatives
8.3.5.5 SWOT analysis
8.3.8 LG LIFE SCIENCES LTD ( LG CHEM)
8.3.8.1 Company overview
8.3.8.2 Financial performance
8.3.8.3 Product benchmarking
8.3.8.4 Strategic initiatives
8.3.8.5 SWOT analysis
8.3.9 SALIX PHARMACEUTICALS
8.3.9.1 Company overview
8.3.9.2 Financial performance
8.3.9.3 Product benchmarking
8.3.9.4 Strategic initiatives
8.3.9.5 SWOT analysis
8.3.10 FIDIA FARMACEUTIC S.P.A
8.3.10.1 Company overview
8.3.10.2 Financial performance
8.3.10.3 Product benchmarking
8.3.10.4 Strategic initiatives
8.3.11 F.HOFFMANN-LA ROCHE LTD.
8.3.11.1 Company overview
8.3.11.2 Financial performance
8.3.11.3 Product benchmarking
8.3.11.4 Strategic initiatives
8.3.11.5 SWOT analysis
Chapter 9 Recommendations
9.1 Recommendations
Chapter 10 Research Methodology & Scope
10.1 Market Segmentation & Scope
10.2 Research Methodology
10.3 Information Procurement
10.3.1 Purchased Database
10.3.2 Internal Database
10.3.3 Secondary Sources
10.3.4 Primary Research
10.3.5 Details Of Primary ResearcH
10.4 Information or Data Analysis
10.4.1 Data Analysis Models
10.5 Market Formulation & Validation
10.6 Model Details
10.6.1 Volume Price Analysis
10.6.2 Commodity Flow Analysis
10.7 List of Secondary Sources
10.8 List of Abbreviations
Chapter 11 Report FAQs
11.1 How do I trust your report quality/data accuracy?
11.2 My research requirement is very specific; can I customize this report?
11.3 I have a pre-defined budget. Can I buy chapters/sections of this report?
11.4 How do you arrive at these market numbers?
11.5 Who are your clients?
11.6 How will I receive this report?
Chapter 12 Appendix
Chapter 13 Compass - Cloud Based Report Delivery Platform
Chapter 14 Related Reports
1.1 Objectives
1.1.1 Objective 1
1.1.2 Objective 2
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.2.1 Product
2.2.2 End-Use
2.2.3 Region
2.3 Competitive Insights
Chapter 3 Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Market Segmentation
3.3 User Perspective Analysis
3.3.1 Consumer Behavior Analysis
3.3.2 Market Influencer Analysis
3.4 Penetration & Growth Prospect Mapping
3.4.1 Analysis
3.5 Market Dynamics
3.5.1 Market Driver Analysis
3.5.1.1 Increasing prevalence of osteoarthritis among geriatric population
3.5.1.2 New product launch
3.5.2 Market Restraint Analysis
3.5.2.1 High cost and side effects associated with hyaluronic acid cycles
3.6 Business Environment Analysis Tools
3.6.1 Porter’s Five Forces Analysis
3.6.2 Viscosupplementation Market - Pestle Analysis
3.7 Clinical Trials
3.8 Major Deals & Strategic Alliances Analysis
3.8.1 Licensing & Partnerships, Technology Collaborations
3.8.2 Mergers & Acquisitions
Chapter 4 Viscosupplementation Market: Product Analysis
4.1 Viscosupplementation Product Market Share analysis, 2019 & 2027
4.2 Segment Dashboard
4.3 Market Size & Forecasts and Trend Analysis, 2016 to 2027 for the Product
4.3.1 Single Injection
4.3.1.1 Single injection market, 2016 - 2027 (USD Million)
4.3.2 Three Injection
4.3.2.1 Three injection market, 2016 - 2027 (USD Million)
4.3.3 Five Injection
4.3.3.1 Five injection market, 2016 - 2027 (USD Million)
4.3.4 Product Information
4.3.4.1 Durolane
4.3.4.2 GelSyn-3
4.3.4.3 GenVisc 850
4.3.4.4 Hymovis
4.3.4.5 Supartz FX
4.3.4.6 TriVisc
4.3.4.7 Visco-3
4.3.4.8 Ostenil
4.3.4.9 Adant
Chapter 5 Viscosupplementation Market: End-Use Analysis
5.1 Viscosupplementation End-Use Market Share analysis, 2019 & 2027
5.2 Segment Dashboard
5.3 Market Size & Forecasts and Trend Analysis, 2016 to 2027 for the End-Use
5.3.1 Hospitals
5.3.1.1 Hospitals market, 2016 - 2027 (USD Million)
5.3.2 Orthopedic Clinics/Ambulatory Surgery Centers (Ascs)
5.3.2.1 Orthopedic clinic/ambulatory surgical centers market, 2016 - 2027 (USD Million)
Chapter 6 Regional Outlook
6.1 Regional Market Share Analysis, 2019 & 2027
6.2 Regional Market Snapshot (Countries)
6.3 SWOT Analysis, by Factor
6.3.1 North America
6.3.2 Europe
6.3.3 Asia Pacific
6.3.4 Latin America
6.3.5 Middle East & Africa
6.4 Market Size, & Forecasts and Trend Analysis, 2019 to 2027
6.4.1 North America
6.4.1.1 North America viscosupplementation market, 2016 - 2027 (USD Million)
6.4.1.2 U.S.
6.4.1.2.1 Regulatory and reimbursement scenario
6.4.1.2.2 U.S. viscosupplementation market, 2016 - 2027 (USD Million)
6.4.1.3 Canada
6.4.1.3.1 Regulatory and reimbursement scenario
6.4.1.3.2 Canada viscosupplementation market, 2016 - 2027 (USD Million)
6.4.2 Europe
6.4.2.1 Europe viscosupplementation market, 2016 - 2027 (USD Million)
6.4.2.2 U.K.
6.4.2.2.1 Regulatory and reimbursement scenario
6.4.2.2.2 U.K. viscosupplementation market, 2016 - 2027 (USD Million)
6.4.2.3 Germany
6.4.2.3.1 Regulatory and reimbursement scenario
6.4.2.3.2 Germany viscosupplementation market, 2016 - 2027 (USD Million)
6.4.2.4 France
6.4.2.4.1 Regulatory and reimbursement scenario
6.4.2.4.2 France viscosupplementation market, 2016 - 2027 (USD Million)
6.4.2.5 Italy
6.4.2.5.1 Regulatory and reimbursement scenario
6.4.2.5.2 Italy viscosupplementation market, 2016 - 2027 (USD Million)
6.4.2.6 Spain
6.4.2.6.1 Regulatory and reimbursement scenario
6.4.2.6.2 Spain viscosupplementation market, 2016 - 2027 (USD Million)
6.4.3 Asia Pacific
6.4.3.1 Asia Pacific viscosupplementation market, 2016 - 2027 (USD Million)
6.4.3.2 China
6.4.3.2.1 Regulatory and reimbursement scenario
6.4.3.2.1 China viscosupplementation market, 2016 - 2027 (USD Million)
6.4.3.3 Japan
6.4.3.3.1 Regulatory and reimbursement scenario
6.4.3.3.2 Japan viscosupplementation market, 2016 - 2027 (USD Million)
6.4.3.4 India
6.4.3.4.1 Regulatory and reimbursement scenario
6.4.3.4.2 India viscosupplementation market, 2016 - 2027 (USD Million)
6.4.3.5 South Korea
6.4.3.5.1 Regulatory and reimbursement scenario
6.4.3.5.2 South Korea viscosupplementation market, 2016 - 2027 (USD Million)
6.4.3.6 Australia
6.4.3.6.1 Regulatory and reimbursement scenario
6.4.3.6.2 Australia viscosupplementation market, 2016 - 2027 (USD Million)
6.4.4 Latin America
6.4.4.1 Latin America viscosupplementation market, 2016 - 2027 (USD Million)
6.4.4.2 Brazil
6.4.4.2.1 Regulatory and reimbursement scenario
6.4.4.2.2 Brazil viscosupplementation market, 2016 - 2027 (USD Million)
6.4.4.3 Mexico
6.4.4.3.1 Regulatory and reimbursement scenario
6.4.4.3.2 Mexico viscosupplementation market, 2016 - 2027 (USD Million)
6.4.4.4 Argentina
6.4.4.4.1 Regulatory and reimbursement scenario
6.4.4.4.2 Argentina viscosupplementation market, 2016 - 2027 (USD Million)
6.4.4.5 Columbia
6.4.4.5.1 Regulatory and reimbursement scenario
6.4.4.5.2 Columbia viscosupplementation market, 2016 - 2027 (USD Million)
6.4.5 Middle East & Africa
6.4.5.1 MEA viscosupplementation market, 2016 - 2027 (USD Million)
6.4.5.2 South Africa
6.4.5.2.1 Regulatory and reimbursement scenario
6.4.5.2.2 South africa viscosupplementation market, 2016 - 2027 (USD Million)
6.4.5.3 Saudi Arabia
6.4.5.3.1 Regulatory and reimbursement scenario
6.4.5.3.2 Saudi Arabia viscosupplementation market, 2016 - 2027 (USD Million)
6.4.5.4 UAE
6.4.5.4.1 Regulatory and reimbursement scenario
6.4.5.4.2 UAE viscosupplementation market, 2016 - 2027 (USD Million)
Chapter 7 Reimbursement Outlook
7.1 Direct Medical Costs of Treatment of Osteoarthritis (Percentage Distribution)
7.2 Cost of Products
7.3 Reimbursement by Product
7.3.1 Gel-One
7.3.2 Euflexxa
7.3.3 Synvisc-One
7.3.4 Supartz
7.3.5 Hyalgan
7.3.6 Monovisc
7.3.7 Orthovisc
Chapter 8 Competitive Analysis
8.1 Strategic Framework/ Competition Categorization (Key innovators, Market leaders, emerging players
8.2 Vendor Landscape
8.2.1 Company Market Position Analysis (Market Presence, Geographic Presence, Product Portfolio, Startegic Initiatves)
8.3 Company Profiles
8.3.1 SANOFI
8.3.1.1 Company overview
8.3.1.2 Financial performance
8.3.1.3 Product benchmarking
8.3.1.4 Strategic initiatives
8.3.1.5 SWOT analysis
8.3.2 ANIKA THERAPEUTICS, INC.
8.3.2.1 Company overview
8.3.2.2 Financial performance
8.3.2.3 Product benchmarking
8.3.2.4 Strategic initiatives
8.3.2.5 SWOT analysis
8.3.3 SEIKAGAKU CORPORATION
8.3.3.1 Company overview
8.3.3.2 Financial performance
8.3.3.3 Product benchmarking
8.3.3.4 Strategic initiatives
8.3.3.5 SWOT analysis
8.3.4 ZIMMER BIOMET
8.3.4.1 Company overview
8.3.4.2 Financial performance
8.3.4.3 Product benchmarking
8.3.4.4 Strategic initiatives
8.3.4.5 SWOT analysis
8.3.5 SMITH & NEPHEW PLC
8.3.5.1 Company overview
8.3.5.2 Financial performance
8.3.5.3 Product benchmarking
8.3.5.4 Strategic initiatives
8.3.5.5 SWOT analysis
8.3.6 FERRING B.V.
8.3.6.1 Company overview
8.3.6.2 Financial performance
8.3.6.3 Product benchmarking
8.3.6.4 Strategic initiative
8.3.7 LIFECORE BIOMEDICAL, LLC (LANDEC)
8.3.7.1 Company overview
8.3.7.2 Financial performance
8.3.7.3 Product benchmarking
8.3.7.4 Strategic initiatives
8.3.5.5 SWOT analysis
8.3.8 LG LIFE SCIENCES LTD ( LG CHEM)
8.3.8.1 Company overview
8.3.8.2 Financial performance
8.3.8.3 Product benchmarking
8.3.8.4 Strategic initiatives
8.3.8.5 SWOT analysis
8.3.9 SALIX PHARMACEUTICALS
8.3.9.1 Company overview
8.3.9.2 Financial performance
8.3.9.3 Product benchmarking
8.3.9.4 Strategic initiatives
8.3.9.5 SWOT analysis
8.3.10 FIDIA FARMACEUTIC S.P.A
8.3.10.1 Company overview
8.3.10.2 Financial performance
8.3.10.3 Product benchmarking
8.3.10.4 Strategic initiatives
8.3.11 F.HOFFMANN-LA ROCHE LTD.
8.3.11.1 Company overview
8.3.11.2 Financial performance
8.3.11.3 Product benchmarking
8.3.11.4 Strategic initiatives
8.3.11.5 SWOT analysis
Chapter 9 Recommendations
9.1 Recommendations
Chapter 10 Research Methodology & Scope
10.1 Market Segmentation & Scope
10.2 Research Methodology
10.3 Information Procurement
10.3.1 Purchased Database
10.3.2 Internal Database
10.3.3 Secondary Sources
10.3.4 Primary Research
10.3.5 Details Of Primary ResearcH
10.4 Information or Data Analysis
10.4.1 Data Analysis Models
10.5 Market Formulation & Validation
10.6 Model Details
10.6.1 Volume Price Analysis
10.6.2 Commodity Flow Analysis
10.7 List of Secondary Sources
10.8 List of Abbreviations
Chapter 11 Report FAQs
11.1 How do I trust your report quality/data accuracy?
11.2 My research requirement is very specific; can I customize this report?
11.3 I have a pre-defined budget. Can I buy chapters/sections of this report?
11.4 How do you arrive at these market numbers?
11.5 Who are your clients?
11.6 How will I receive this report?
Chapter 12 Appendix
Chapter 13 Compass - Cloud Based Report Delivery Platform
Chapter 14 Related Reports
Note: Product cover images may vary from those shown
- SANOFI
- ANIKA THERAPEUTICS, INC.
- SEIKAGAKU CORPORATION
- ZIMMER BIOMET
- SMITH & NEPHEW PLC
- FERRING B.V.
- LIFECORE BIOMEDICAL, LLC (LANDEC)
- LG LIFE SCIENCES LTD (LG CHEM)
- SALIX PHARMACEUTICALS
- FIDIA FARMACEUTIC S.P.A
- F.HOFFMANN-LA ROCHE LTD.
Note: Product cover images may vary from those shown
LOADING...
